New report shows that the current flu vaccine produces antibodies that efficiently recognize subclade K in 39% of recipients.
The recommendation for vaccines for the next flu season includes a new influenza variant—subclade K—that started to increase last fall.
If the recommendation is accepted by the European Commission, Moderna's mCombriax vaccine will be available for adults 50 and older throughout the European Union.
A new study finds that veterans in a supported housing program from the Department of Veterans Affairs were about 50% more likely to receive a flu shot compared with veterans not enrolled in the program.
A single dose of mRNA-1073 elicited durable immune responses through 6 months against all vaccine-matched influenza and SARS-CoV-2 strains.
So far this season, the CDC estimates that there have been at least 24 million flu-related illnesses, 310,000 hospitalizations, and 20,000 deaths.
The latest FDA reversal is welcome, but the episode of first denying Moderna review of its mRNA flu vaccine deserves close examination.
Between federal lawsuits, sweeping schedule changes, and states mobilizing their own legal challenges, the last few weeks have been a whirlwind. Let's dive right in.
But the spray won’t replace flu vaccination because it stays in the nose for only a few hours.
The FDA had refused to review the original application because it said Moderna’s phase 3 study was not "adequate and well-controlled."
